1. 2020
  2. 2019
  3. Cross-genotype AR3-specific neutralizing antibodies confer long-term protection in injecting drug users after HCV clearance

    Merat, S. J., Bru, C., van de Berg, D., Molenkamp, R., Tarr, A. W., Koekkoek, S., Kootstra, N. A., Prins, M., Ball, J. K., Bakker, A. Q., de Jong, M. D., Spits, H., Beaumont, T. & Schinkel, J., 2019, In: Journal of hepatology. 71, 1, p. 14-24

    Research output: Contribution to journalArticleAcademicpeer-review

  4. Protective antibody responses against HCV E1E2 in high-risk populations

    Merat, S., 2019, 194 p.

    Research output: ThesisPhd-Thesis - Research and graduation internal

  5. 2018
  6. Multiplex flow cytometry-based assay to study the breadth of antibody responses against E1E2 glycoproteins of hepatitis C virus

    Merat, S. J., van de Berg, D., Bru, C., Yasuda, E., Breij, E., Kootstra, N., Prins, M., Molenkamp, R., Bakker, A. Q., de Jong, M. D., Spits, H., Schinkel, J. & Beaumont, T., 2018, In: Journal of immunological methods. 454, p. 15-26

    Research output: Contribution to journalArticleAcademicpeer-review

  7. 2016
  8. Hepatitis C virus Broadly Neutralizing Monoclonal Antibodies Isolated 25 Years after Spontaneous Clearance

    Merat, S. J., Molenkamp, R., Wagner, K., Koekkoek, S. M., van de Berg, D., Yasuda, E., Böhne, M., Claassen, Y. B., Grady, B. P., Prins, M., Bakker, A. Q., de Jong, M. D., Spits, H., Schinkel, J. & Beaumont, T., 2016, In: PLoS ONE. 11, 10, p. e0165047

    Research output: Contribution to journalArticleAcademicpeer-review

ID: 73395